V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160017330 | 160008615 | null | 13.25 | Adjuvant (A) | 2018-04-05 | 2018-04-06 | EW EuroEwing 2012 Arm B VDC | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101791368 |
| 160017331 | 160008616 | 1.83 | 78.5 | Palliative (P) | 2019-11-16 | 2019-11-16 | Trial Unspecified | 02 | N | DOXORUBICIN + OLARATUMAB | 100683540 |
| 160017335 | 160008617 | 1.75 | 75.3 | Neo-adjuvant (N) | 2019-04-27 | 2019-04-27 | EW EuroEwing 2012 Arm A VIDE | 02 | N | CARBOPLATIN + GEMCITABINE | 100789822 |
| 160017336 | 160008618 | 1.53 | 67.9 | Palliative (P) | 2019-06-11 | 2019-06-11 | Doxorubicin + Ifosfamide | 02 | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 100305483 |
| 160017337 | 160008619 | 1.76 | 55 | Adjuvant (A) | 2018-05-08 | 2018-05-19 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 100402879 |
| 160017339 | 160008620 | 1.73 | 92 | Palliative (P) | 2020-05-21 | 2020-06-22 | DOXORUBICIN | null | N | DOXORUBICIN | 101225579 |
| 160017340 | 160008621 | 1.49 | 90 | Not known (9) | 2016-05-05 | 2016-05-19 | Imatinib 400mg | 02 | N | CISPLATIN + PEMETREXED | 100474883 |
| 160017342 | 160008622 | 1.81 | 105.3 | Palliative (P) | 2018-12-04 | 2018-12-06 | null | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100659435 |
| 160017350 | 160008623 | 1.74 | 76.5 | Curative (C) | 2019-01-19 | 2019-01-21 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101670923 |
| 160017353 | 160008624 | 1.67 | 80.3 | null | 2020-01-09 | 2020-01-20 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101144008 |
| 160017354 | 160008625 | 1.71 | 77.2 | null | null | 2016-12-09 | PARTNER Trial | 2 | N | ETOP 13-18 BEAT-MESO TRIAL | 101603955 |
| 160017355 | 160008626 | 1.81 | 72.3 | Palliative (P) | 2019-02-17 | 2019-02-18 | Vinorelbine (oral) | 02 | N | EW EUROEWING 2012 ARM B VDC | 101578046 |
| 160017356 | 160008627 | 1.73 | 77.7 | Palliative (P) | 2016-08-20 | 2016-08-23 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100674741 |
| 160017358 | 160008628 | 1.71 | 108 | Neo-adjuvant (N) | 2017-06-14 | 2017-06-21 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100480278 |
| 160017360 | 160008629 | 1.83 | null | Palliative (P) | 2016-08-02 | 2016-08-19 | ETOP 13-18 BEAT-meso Trial | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100725871 |
| 160017368 | 160008631 | 1.7 | 78.2 | Curative (C) | 2019-10-31 | 2019-11-03 | Doxorubicin 75mg/m2 | N | N | CYCLOPHOSPHAMIDE | 100250842 |
| 160017369 | 160008632 | 1.84 | 55 | Palliative (P) | null | 2017-03-25 | STS Rhabdomyosarcoma RMS 2005 IVAVV | N | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101146230 |
| 160017370 | 160008633 | 1.63 | null | Palliative (P) | 2018-02-24 | 2018-02-24 | Doxorubicin + Ifosfamide | N | N | CISPLATIN + CYCLOPHOSPHAMIDE + DOXORUBICIN | 100721352 |
| 160017372 | 160008634 | 1.8 | 65 | Palliative (P) | 2017-04-21 | 2017-04-28 | LANREOTIDE | N | N | ETOP 13-18 BEAT-MESO TRIAL | 100317776 |
| 160017374 | 160008635 | 1.63 | 79.5 | Neo-adjuvant (N) | 2019-09-03 | 2019-09-07 | EW EuroEwing 2012 Arm A VIDE | 02 | N | HYDROXYCARBAMIDE | 100421031 |
| 160017375 | 160008636 | 1.71 | 24.4 | Palliative (P) | 2019-08-09 | 2019-08-15 | null | 02 | N | BLEOMYCIN + CISPLATIN + ETOPOSIDE | 101613656 |
| 160017376 | 160008637 | 1.65 | null | Neo-adjuvant (N) | 2020-02-07 | 2020-02-07 | IVADo | 02 | N | CISPLATIN + ETOPOSIDE | 100140092 |
| 160017378 | 160008638 | 1.65 | 84.2 | Curative (C) | 2016-06-23 | 2016-06-25 | Carboplatin + Paclitaxel (3 weekly) | null | N | CARBOPLATIN + PACLITAXEL | 100810764 |
| 160017381 | 160008639 | null | null | Palliative (P) | 2018-08-07 | 2018-08-13 | Pemetrexed | 2 | null | NB LOW/INTERM RISK GUIDELINES CARBO/ETOP | 100927627 |
| 160017382 | 160008640 | 1.6 | 75 | Palliative (P) | 2016-05-13 | 2016-05-27 | Liposomal Doxorubicin (Caelyx) | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100578458 |
| 160017385 | 160008641 | 1.71 | 100.5 | Palliative (P) | 2018-04-25 | 2018-04-30 | Cisplatin + Pemetrexed | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100674697 |
| 160017388 | 160008642 | 1.74 | 74.4 | Curative (C) | 2019-08-11 | 2019-09-02 | DOXORUBICIN | 02 | N | CARBOPLATIN | 101109548 |
| 160017390 | 160008643 | 1.79 | 100 | Palliative (P) | 2019-08-27 | 2019-08-27 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100851729 |
| 160017393 | 160008644 | 1.72 | 60.9 | Neo-adjuvant (N) | 2016-09-09 | 2016-09-10 | Trial Unspecified | 01 | N | CISPLATIN + DOXORUBICIN | 100809168 |
| 160017395 | 160008645 | 1.75 | 71.6 | Neo-adjuvant (N) | 2017-07-19 | 2017-07-19 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101824416 |
| 160017396 | 160008646 | 1.68 | 78.8 | Disease modification (D) | 2018-04-11 | 2018-04-19 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 01 | N | BEVACIZUMAB + CARBO + PACLITAXEL | 101280426 |
| 160017398 | 160008647 | 1.74 | 72 | Palliative (P) | 2020-01-30 | 2020-02-10 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 100262428 |
| 160017400 | 160008648 | 1.64 | 81.25 | null | null | 2019-04-06 | EOX | null | Y | CISPLATIN + PEMETREXED | 100249403 |
| 160017401 | 160008649 | 1.72 | 82.9 | null | 2022-02-10 | 2022-02-10 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + OBINUTUZUMAB + VINCRISTINE | 100131402 |
| 160017402 | 160008650 | 1.68 | 61.2 | Palliative (P) | 2018-10-23 | 2018-11-02 | TALIMOGENE LAHERPAREPVEC | 02 | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101771503 |
| 160017403 | 160008651 | 1.74 | 55.7 | Neo-adjuvant (N) | 2016-02-14 | 2016-02-25 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101298714 |
| 160017404 | 160008652 | 1.7 | 73.2 | Neo-adjuvant (N) | 2016-10-16 | 2016-10-18 | Doxorubicin + Ifosfamide | 02 | N | DOXORUBICIN | 100331605 |
| 160017406 | 160008653 | 1.56 | 55 | Palliative (P) | 2019-08-07 | 2019-08-07 | Cisplatin + Pemetrexed | 02 | N | OXALIPLATIN + MDG | 101715816 |
| 160017407 | 160008654 | 1.67 | 83 | Palliative (P) | 2016-08-02 | 2016-08-16 | Doxorubicin + Ifosfamide | 02 | null | PEMETREXED | 100811708 |
| 160017408 | 160008655 | 1 | 54.4 | Curative (C) | 2017-07-14 | 2017-07-14 | Doxorubicin + Olaratumab | 02 | N | DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 100720759 |
| 160017409 | 160008656 | 1.74 | 53 | Palliative (P) | 2019-02-11 | 2019-02-12 | Trial Unspecified | 02 | N | LIPOSOMAL DOXORUBICIN | 100792911 |
| 160017413 | 160008657 | 1.67 | 66.2 | Curative (C) | 2016-05-10 | 2016-05-12 | Cisplatin + Pemetrexed | 02 | N | BEP | 100878063 |
| 160017416 | 160008658 | 1.6 | 76.4 | Palliative (P) | 2014-11-08 | 2017-10-25 | CARBOPLATIN | 02 | N | CARBOPLATIN | 101132440 |
| 160017417 | 160008659 | 1.75 | 85.8 | Curative (C) | 2019-12-21 | 2019-12-27 | Paclitaxel 7 day | 02 | N | TRIAL UNSPECIFIED | 101083476 |
| 160017418 | 160008660 | 1.67 | 70.55 | Palliative (P) | 2020-08-16 | 2020-08-25 | PACLITAXEL | 02 | N | CAPECITABINE + CARBOPLATIN + EPIRUBICIN | 100627889 |
| 160017419 | 160008661 | 1.67 | 77.8 | Adjuvant (A) | 2016-05-22 | 2016-05-24 | DOXORUBICIN | 02 | N | DOXORUBICIN | 100343892 |
| 160017421 | 160008662 | 1.46 | 104.5 | Palliative (P) | 2019-03-08 | 2019-03-08 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100612534 |
| 160017422 | 160008663 | 1.79 | 99 | Palliative (P) | 2019-12-01 | 2019-12-01 | Cisplatin + Pemetrexed | Y | null | CISPLATIN + PEMETREXED | 100534873 |
| 160017424 | 160008664 | 1.8 | 68.7 | Palliative (P) | 2017-12-11 | 2017-12-11 | Doxorubicin + Ifosfamide | null | N | DOXORUBICIN + OLARATUMAB | 101193747 |
| 160017427 | 160008665 | 1.8 | 86.6 | Curative (C) | null | 2018-02-18 | NB HRNBL-1 MOD N7 CAV | 02 | N | TRIAL UNSPECIFIED | 101837929 |